MA-IBASIS
14.5.2024 14:01:39 CEST | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Altice Dominicana, one of the leading mobile networks in the Dominican Republic, announced today that they have renewed their successful outsourcing agreement for voice services.
Since its sale by Altice in 2018, iBASIS and its global team have been dedicated to bringing Altice Dominicana best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. iBASIS has helped to drive the Dominican operator’s performance, monetization, and profitability through its differentiated model, international expertise, and exclusive Inbound Gateway. Key focus areas, including cost improvement and fraud prevention, have also played a pivotal role in supporting Altice Dominicana’s sustained traffic growth.
“iBASIS demonstrated their commitment to deliver value across many facets of our international business. Their offerings and expertise, specifically in addressing international requirements, enable us to make significant service quality enhancements and cost improvements,” said Jennifer Espinal, International Business Manager at Altice Dominicana. “The strategic relationship, including the exclusive Inbound Gateway, is essential for maintaining our growth trajectory and securing our leading position in the region. We are also fortifying this collaboration and expanding into mobile services in order to capitalize on the growth of inbound roaming traffic.”
The Dominican Republic has experienced remarkable growth in tourism, witnessing a 14% increase in international visitors in 2023 compared to 2019, surpassing 10 million travelers for the first time.* Ensuring excellent roaming performance and experience is crucial in such an appealing destination for foreign visitors.
“With Altice Dominicana, we share the same goal of providing state-of-the-art connectivity and supporting innovations to unleash the potential of international communications,” said Edwin van Ierland, CEO of Voice & Mobile Data at iBASIS. “Thanks to our global platforms, capabilities, and highly motivated teams, iBASIS is a high-growth partner and is helping Altice Dominicana to continue to perform at the highest level.”
“The renewal with Altice Dominicana marks another significant milestone, highlighting the appeal of iBASIS's outsourcing proposition," remarked Alexandre Pébereau, Group CEO and Founder of Tofane Global. "By overseeing the entire spectrum of international voice and mobile communications for them, our customers can concentrate on their retail business, foster growth, and sustain their dominant market position.”
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. For more information, please visit iBASIS.com.
ABOUT Altice Dominicana
Altice Dominicana is one of the main telecommunications companies in the Dominican Republic, with a decade-long history of offering connectivity and entertainment services.
Its robust mobile network has 98% coverage nationwide; With an extensive fiber optic network infrastructure, it provides Internet with the highest speed available on the market, up to 1,000 MB, cable television and high definition voice services to more than 4 million homes and businesses throughout the country.
Through its human team, agile, with challenging and daring thinking, it promotes innovation in everything it does and demonstrates its commitment to each of the Dominicans in providing them with access to technology to boost their growth opportunities.
*2023 Global Travel Trends Report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514293879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom